Skip to main content
SLU publication database (SLUpub)

Research article2021Peer reviewedOpen access

Serum concentrations of Thymidine kinase 1 measured using a novel antibody-based assay in patients with Hodgkin Lymphoma

Ulfstedt, Johan Mattsson; Venge, Per; Holmgren, Sofia; Enblad, Gunilla; Eriksson, Staffan; Molin, Daniel


Background: Thymidine kinase 1 (TK1) is an intracellular protein associated with DNA synthesis, expressed during the G1 phase and remained elevated through the M phase, with a potential as a biomarker for cell proliferation. In this study, we explore the possible use of TK1 in Hodgkin lymphoma (HL).Methods: Serum concentrations of TK1 (S-TK1) were measured in 46 newly diagnosed HL patients using prospectively collected biobanked serum samples. The samples were analyzed using a novel antibody-based TK1 immunosorbent assay (ELISA).Results: The concentrations of S-TK1 were elevated in HL patients compared with healthy controls (median 0.32 mu g/L vs. 0.24 mu g/L, P = 0.003). A further increase in S-TK1 was observed during the treatment. The S-TK1 concentrations were higher in patients with advanced stage disease, low B-Hb, elevated P-LD and in those with B-symptoms. A high ESR correlated with low S-TK1.Conclusions: The study results suggest that S-TK1, measured using a novel antibody-based assay, has the potential to be a biomarker in HL. However, while S-TK1 levels are elevated at baseline compared with healthy controls, a limited number of patients and comparatively short follow-up time render reliable -conclusions difficult.


Hodgkin lymphoma; TK1; Thymidine kinase; prognostic markers; chemotherapy

Published in

Upsala Journal of Medical Sciences
2021, Volume: 126, number: 1, article number: e6119

    UKÄ Subject classification

    Immunology in the medical area

    Publication identifier


    Permanent link to this page (URI)